A clinical trial to study the effects of additional treatments for patients hospitalized and receiving treatment due to COVID -19.

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Plus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024773

Enrollment

10000

Registered

2020-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Imatinib: Imatinib, orally once daily for 14 days along with local standard of care Intervention2: Infliximab: Infliximab, as a single IV infusion along with local standard care treat

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults (age >=18 years) recently hospitalised, or already in the hospital, with definite (diagnosed by RT-PCR) symptomatic COVID admitted for at least moderate or severe illness 2. In the view of the responsible doctor, no contra-indication to any of the study drugs. 3. Providing consent for the participation

Exclusion criteria

Exclusion criteria: 1.Adults (age >=18 years) with COVID and hospitalised for quarantine purposes or management of other conditions who do not have moderate or severe illness. 2.Laboratory confirmation of SARS Cov -2 infection not available 3.In the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra-indicated Anticipated transfer to another hospital which is not a study site within 72 hours 4.Pregnant or Lactating Women

Design outcomes

Primary

Measure	Time frame
All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the studyTimepoint: Throughout the study	—

Secondary

Measure	Time frame
Measured using patient records: 1. Duration of hospital stay (hours) 2. Time to first receiving ventilation (or intensive care) (hours)Timepoint: Measured using patient records: 1. Duration of hospital stay (hours) 2. Time to first receiving ventilation (or intensive care) (hours)	—

Countries

Albania, Argentina, Bahamas, Bangladesh, Belize, Bolivia, Botswana, Brazil, Canada, Colombia, Dominica, Dominican Republic, Ecuador, Egypt, Ethiopia, Finland, Georgia, Guyana, Honduras, India, Indonesia, Iran (Islamic Republic of), Ireland, Italy, Jamaica, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mali, Mexico, Mozambique, Niger, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Portugal, Romania, Saudi Arabia, Sierra Leone, Spain, Switzerland, Trinidad and Tobago, Zimbabwe

Contacts

Public ContactDrSheela Virendra Godbole

ICMR-National AIDS Research Institute, Pune

sgodbole@nariindia.org09422087972

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026